ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,555.74
      -0.16%
      US Tech 100
      19,193.60
      -0.58%
      Dow Jones
      40,358.09
      -0.14%
      Brent Oil
      80.77
      -0.91%
      Bitcoin
      65,979.54
      -2.38%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Longboard Pharmaceuticals Inc (LBPH) Quote

      Longboard Pharmaceuticals Inc

      Longboard Pharmaceuticals Inc (LBPH)

      NASDAQ
      33.60
      -3.18
      (-8.65%)
      At close: July 23 4:00PM
      Delayed by 15 minutes
      33.60
      0.00
      ( 0.00% )
      After Hours: 4:53PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      33.60
      Bid
      33.80
      Ask
      34.52
      Volume
      1,298,761
      32.45 Day's Range 36.88
      3.60 52 Week Range 40.48
      Market Cap
      1.306B
      Previous Close
      36.78
      Open
      36.67
      Last Trade
      45
      @
      33.81
      Last Trade Time
      17:03:58
      Financial Volume
      $ 44,560,913
      VWAP
      34.3103
      Average Volume (3m)
      513,468
      Shares Outstanding
      38,880,054
      Dividend Yield
      -
      PE Ratio
      -24.01
      Earnings Per Share (EPS)
      -1.4
      Revenue
      -
      Net Profit
      -54.42M

      About Longboard Pharmaceuticals Inc

      Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659. Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.longboardpharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Longboard Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LBPH. The last closing price for Longboard Pharmaceuticals was $36.78. Over the last year, Longboard Pharmaceuticals shares have traded in a share price range of $ 3.60 to $ 40.48.

      Longboard Pharmaceuticals currently has 38,880,054 shares outstanding. The market capitalization of Longboard Pharmaceuticals is $1.43 billion. Longboard Pharmaceuticals has a price to earnings ratio (PE ratio) of -24.01.

      Longboard Pharmaceuticals (LBPH) Options Flow Summary

      LBPH Options Flow

      Overall Flow

      Bullish

      Net Premium

      32k

      Calls / Puts

      100.00%

      Buys / Sells

      0.00%

      OTM / ITM

      0.00%

      Sweeps Ratio

      0.00%

      LBPH Latest News

      More News

      Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

      July 03 2024
      Business Wire

      Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

      U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies...

      July 01 2024
      Business Wire

      Form 8-K - Current report

      June 10 2024
      Edgar (US Regulatory)

      Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

      Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group...

      June 10 2024
      Business Wire

      Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

      June 03 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      May 24 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      May 24 2024
      Edgar (US Regulatory)

      Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

      May 06 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-6.2-15.577889447239.840.39532.4559075436.96939877CS
      412.7360.996645903220.8740.4819.659797169831.79610793CS
      1212.559.241706161121.140.4815.6451346827.39146818CS
      268.5233.97129186625.0840.4815.6454829923.58613485CS
      5226.38365.3739612197.2240.483.655668823.02998316CS
      15624.9286.2068965528.740.482.721144421.02830377CS
      26017.61101640.482.719551620.68620083CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ALLRAllarity Therapeutics Inc
      $ 0.2901
      (74.23%)
      		35.57M
      NIVFNewGenIvf Group Ltd
      $ 1.46
      (67.64%)
      		3.46M
      SLNASelina Hospitality PLC
      $ 0.031
      (19.23%)
      		35.07M
      DRMADermata Therapeutics Inc
      $ 1.44
      (10.77%)
      		92.23k
      TRIBTrinity Biotech PLC
      $ 3.35
      (9.48%)
      		826
      VSTMVerastem Inc
      $ 2.67
      (-25.63%)
      		365.05k
      SLRXSalarius Pharmaceuticals Inc
      $ 2.17
      (-16.86%)
      		202.8k
      ALPPAlpine 4 Holdings Inc
      $ 0.5119
      (-14.67%)
      		283.36k
      CJETChijet Motor Company Inc
      $ 4.36
      (-14.17%)
      		87.52k
      GERNGeron Corp
      $ 4.01
      (-13.20%)
      		546.62k
      ALLRAllarity Therapeutics Inc
      $ 0.2901
      (74.23%)
      		35.57M
      SLNASelina Hospitality PLC
      $ 0.031
      (19.23%)
      		35.07M
      TSLATesla Inc
      $ 235.97
      (-4.23%)
      		11.77M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 12.52
      (-8.61%)
      		9.95M
      HOLOMicroCloud Hologram Inc
      $ 0.6139
      (4.98%)
      		8.34M

      LBPH Discussion

      View Posts
      TechandBio TechandBio 2 weeks ago
      MY best performing Bio this year! Surfs up Vertical debit spreads from $5.00 are up over 1430% wish i went heavier keep an eye on ICCM

      $LBPH
      👍️0
      da_stock_analyst da_stock_analyst 7 months ago
      #LBPH 🔥 short squeeze might push this way higher! Nice set up!
      👍️0
      Backstabbed Backstabbed 7 months ago
      Insane … grats all
      👍️0
      conix conix 7 months ago
      LOTTO Ticket for 2024: Curative Biotechnology $CUBT @ $0.02 is a biotech with some very promising technology in the treatment of Age-Related Macular Degeneration (AMD). Metformin, a widely used diabetes drug, has been proven to have positive effects on patients with AMD. CUBT has a patented formulation for the direct delivery of metformin to the eye in the form of eye drops. The National Institutes of Health (NIH) will be funding a clinical trial on humans in 2024 in collaboration with the company. There has been a number of delays in the start of the trials, hence the low price, but the price has been firming up this past month. Although difficult to predict when these announcements happen, at these prices, CUBT is worth buying a small position (you can define "small") to make certain you are following the news and the price reaction so you can average up on your original position. Check the CUBT website out to see more info on the trials and the company's other drugs in the pipeline. Target Price by end of First Quarter (assuming clinical trial announcement)--$0.15).

      SOURCE: https://www.reddit.com/r/pennystocks/comments/18uvm1j/trading_ideas_for_january_sing_migi_cubtmentioned/

      It should go without saying, BUT some may need to read it...the above is someone's opinion. Nice to see anyways.
      👍️0
      conix conix 7 months ago
      Congrats on being a quick thinker. Per-market buying can be risky, but does pan out.
      👍️0
      TheFinalCD TheFinalCD 7 months ago
      The company has 9.5 months of cash left based on quarterly cash burn of -$13.28M and estimated current cash of $42.0M.
      https://dilutiontracker.com/app/search/LBPH?a=dbb88c
      👍️0
      Stockexpertpro Stockexpertpro 7 months ago
      AVTX Data Due on Watch here after 1 for 240 RS micro Float
      👍️0
      Laster Laster 7 months ago
      Grabbed some at 8am immediately following news.
      Looking good moving into open.
      Sold half on double. Riding rest free.
      What a way to start 2024!
      👍️0
      Monksdream Monksdream 7 months ago
      Early Barchart 100
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0
      tw0122 tw0122 7 months ago
      An epileptic profit nice…
      👍️0
      cityimport cityimport 7 months ago
      My First Almost 200% Profit (Within One Hour) In 2024 ... :)))))))))))))

      In @ 6.25
      Out @ 17.95

      LBPH
      👍️0

      Your Recent History

      NASDAQ
      LBPH
      Longboard Pharmaceuticals
      NASDAQ
      ABSI
      AbSci
      TG
      1N31
      NewtekOne
      TG
      0R1
      Royal Unibrew AS
      Delayed Upgrade Clock